{"id":"https://openalex.org/W2016589872","doi":"https://doi.org/10.1038/sj.bjp.0706686","title":"Delta opioid receptor ligands modulate anxiety\u2010like behaviors in the rat","display_name":"Delta opioid receptor ligands modulate anxiety\u2010like behaviors in the rat","alternate_titles":[],"publication_year":2006,"publication_date":"2006-02-20","ids":{"openalex":"https://openalex.org/W2016589872","doi":"https://doi.org/10.1038/sj.bjp.0706686","mag":"2016589872","pmid":"https://pubmed.ncbi.nlm.nih.gov/16491101","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1760715"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjp.0706686","doi":"https://doi.org/10.1038/sj.bjp.0706686","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjp.0706686","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0706686","source":{"id":"https://openalex.org/S55107261","display_name":"British Journal of Pharmacology","issn_l":"0007-1188","issn":["0007-1188","1476-5381"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2016589872"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0706686","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004809245","display_name":"Shane Alan Perrine","orcid":"https://orcid.org/0000-0001-6983-2372","observed_orcids":["https://orcid.org/0000-0001-6983-2372"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Shane A Perrine","raw_affiliation_strings":["Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA. perrines@temple.edu","Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA. perrines@temple.edu","institution_ids":["https://openalex.org/I84392919"]},{"raw_affiliation_string":"Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079146939","display_name":"Brian A. Hoshaw","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian A Hoshaw","raw_affiliation_strings":["Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, U.S.A","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008721084","display_name":"Ellen M. Unterwald","orcid":"https://orcid.org/0000-0001-5391-7507","observed_orcids":["https://orcid.org/0000-0001-5391-7507"]},"institutions":[{"id":"https://openalex.org/I83399316","display_name":"Rockefeller University","ror":"https://ror.org/0420db125","country_code":"US","type":"education","lineage":["https://openalex.org/I83399316"]},{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ellen M Unterwald","raw_affiliation_strings":["Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A","The Rockefeller University, New York, NY, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A","institution_ids":["https://openalex.org/I84392919"]},{"raw_affiliation_string":"The Rockefeller University, New York, NY, U.S.A","institution_ids":["https://openalex.org/I83399316"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5004809245"],"corresponding_institution_ids":["https://openalex.org/I84392919"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":2.1316,"has_fulltext":true,"cited_by_count":154,"citation_normalized_percentile":{"value":0.85807639,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"147","issue":"8","first_page":"864","last_page":"872"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.9599999785423279,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.9599999785423279,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.03700000047683716,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13047","display_name":"Pharmacological Receptor Mechanisms and Effects","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/delta-opioid-receptor","display_name":"delta opioid receptor","score":0.996999979019165},{"id":"https://openalex.org/keywords/anxiety-like-behavior","display_name":"anxiety-like behavior","score":0.9200000166893005},{"id":"https://openalex.org/keywords/naltrindole","display_name":"naltrindole","score":0.9240000247955322},{"id":"https://openalex.org/keywords/snc80","display_name":"SNC80","score":0.9900000095367432},{"id":"https://openalex.org/keywords/anxiolytic-effects","display_name":"anxiolytic effects","score":0.906000018119812},{"id":"https://openalex.org/keywords/anxiogenic-effects","display_name":"anxiogenic effects","score":0.9919999837875366},{"id":"https://openalex.org/keywords/diazepam","display_name":"diazepam","score":0.906000018119812},{"id":"https://openalex.org/keywords/amphetamine","display_name":"amphetamine","score":0.8450000286102295},{"id":"https://openalex.org/keywords/locomotor-activity","display_name":"locomotor activity","score":0.9390000104904175},{"id":"https://openalex.org/keywords/hyperlocomotion","display_name":"hyperlocomotion","score":0.777999997138977},{"id":"https://openalex.org/keywords/defensive-burying","display_name":"defensive burying","score":0.8040000200271606},{"id":"https://openalex.org/keywords/elevated-plus-maze","display_name":"elevated plus maze","score":0.7839999794960022}],"concepts":[{"id":"https://openalex.org/C2777953665","wikidata":"https://www.wikidata.org/wiki/Q3743642","display_name":"Naltrindole","level":5,"score":0.9946684837341309},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.7351635694503784},{"id":"https://openalex.org/C173586616","wikidata":"https://www.wikidata.org/wiki/Q5359685","display_name":"Elevated plus maze","level":3,"score":0.643470823764801},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5905123949050903},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5634884238243103},{"id":"https://openalex.org/C2779886867","wikidata":"https://www.wikidata.org/wiki/Q421797","display_name":"Opioid receptor","level":4,"score":0.49604329466819763},{"id":"https://openalex.org/C205044023","wikidata":"https://www.wikidata.org/wiki/Q4778117","display_name":"Anxiogenic","level":4,"score":0.4824998378753662},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.43938788771629333},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4275496006011963},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3267483115196228},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32140052318573},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.28328484296798706},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2577282190322876},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1883767545223236},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.08229672908782959}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001007","descriptor_name":"Anxiety","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017465","descriptor_name":"Receptors, Opioid, delta","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1038/sj.bjp.0706686","doi":"https://doi.org/10.1038/sj.bjp.0706686","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjp.0706686","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0706686","source":{"id":"https://openalex.org/S55107261","display_name":"British Journal of Pharmacology","issn_l":"0007-1188","issn":["0007-1188","1476-5381"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:16491101","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16491101","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1760715","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC1760715/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Pharmacol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1038/sj.bjp.0706686","doi":"https://doi.org/10.1038/sj.bjp.0706686","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjp.0706686","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0706686","source":{"id":"https://openalex.org/S55107261","display_name":"British Journal of Pharmacology","issn_l":"0007-1188","issn":["0007-1188","1476-5381"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8999999761581421}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3582531758","display_name":"Center on Intersystem Regulation by Drugs of Abuse","funder_award_id":"P30DA013429","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G508649659","display_name":null,"funder_award_id":"DA 07237","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G5520316217","display_name":null,"funder_award_id":"NIH-R01","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G6619086776","display_name":"Regulation of delta opioid receptor function by cocaine","funder_award_id":"R01DA018326","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G9000192878","display_name":null,"funder_award_id":"DA07237","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000905427","display_name":"Neurobiology of Addiction Training Program","funder_award_id":"T32DA007237","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2016589872.pdf","grobid_xml":"https://content.openalex.org/works/W2016589872.grobid-xml"},"referenced_works_count":41,"referenced_works":["https://openalex.org/W1183568000","https://openalex.org/W1505495051","https://openalex.org/W1516221483","https://openalex.org/W1942647961","https://openalex.org/W1965868568","https://openalex.org/W1967519053","https://openalex.org/W1967675334","https://openalex.org/W1970238016","https://openalex.org/W1970964820","https://openalex.org/W1978803611","https://openalex.org/W1982309599","https://openalex.org/W1988781968","https://openalex.org/W1990728215","https://openalex.org/W1991438019","https://openalex.org/W1998654972","https://openalex.org/W2000321144","https://openalex.org/W2008181379","https://openalex.org/W2008718590","https://openalex.org/W2008754951","https://openalex.org/W2015995696","https://openalex.org/W2020918975","https://openalex.org/W2022356586","https://openalex.org/W2024418858","https://openalex.org/W2041155806","https://openalex.org/W2041561931","https://openalex.org/W2041877261","https://openalex.org/W2043023167","https://openalex.org/W2056333149","https://openalex.org/W2064708051","https://openalex.org/W2067344526","https://openalex.org/W2072807884","https://openalex.org/W2088133485","https://openalex.org/W2114389459","https://openalex.org/W2120023340","https://openalex.org/W2124854299","https://openalex.org/W2142301604","https://openalex.org/W2206881671","https://openalex.org/W2217559940","https://openalex.org/W2333131869","https://openalex.org/W2399045151","https://openalex.org/W4406061002"],"related_works":["https://openalex.org/W2041155806","https://openalex.org/W2072807884","https://openalex.org/W2091785807","https://openalex.org/W2037120595","https://openalex.org/W2052717003","https://openalex.org/W2131229562","https://openalex.org/W2093090726","https://openalex.org/W4407418473","https://openalex.org/W4365810917","https://openalex.org/W2041088235"],"abstract_inverted_index":{"The":[0],"role":[1],"of":[2,24,57,72,78,113,120,131,146,215,222],"the":[3,22,25,70,87,95,98,114,129,132,143,162,197,203,206,213,232],"delta":[4,27,133,233],"opioid":[5,28,134,234],"receptor":[6,29,135,235],"in":[7,11,125,137,241],"regulating":[8,138],"anxiety-like":[9,47,153,239],"behavior":[10,48,124,240],"male":[12],"Sprague-Dawley":[13],"rats":[14,126],"was":[15,52,84,91],"examined.":[16],"Using":[17],"an":[18,193,242],"elevated":[19,99,198],"plus":[20,100,199],"maze,":[21],"effects":[23,71,109,145,214,224],"selective":[26],"antagonist":[30],"naltrindole":[31,121,166],"(1":[32,64],"or":[33,42],"5":[34,41],"mg":[35,44,60,65],"kg(-1))":[36,45,61,66],"and":[37,62,67,82,167,245],"agonist":[38],"SNC80":[39,105,155,176,216],"(1,":[40],"20":[43],"on":[46,152,196,217,225],"were":[49],"measured.":[50,85],"Anxiety":[51],"also":[53,141],"measured":[54],"following":[55,76],"administration":[56,77],"diazepam":[58,168],"(3":[59],"amphetamine":[63,83,160],"compared":[68],"to":[69,93,111,159,191],"SNC80.":[73,147],"Locomotor":[74],"activity":[75],"naltrindole,":[79],"SNC80,":[80],"diazepam,":[81],"Finally,":[86],"defensive":[88,207],"burying":[89,208],"paradigm":[90],"used":[92],"confirm":[94],"findings":[96],"from":[97,205],"maze.":[101,200],"Results":[102],"demonstrated":[103],"that":[104,112,186,212,231],"produced":[106],"dose-dependent":[107],"anxiolytic":[108,144,194,243],"similar":[110,158],"classical":[115],"antianxiety":[116],"agent,":[117],"diazepam.":[118],"Administration":[119],"caused":[122],"anxiogenic":[123,246],"further":[127],"supporting":[128],"involvement":[130],"system":[136,236],"anxiety.":[139],"Naltrindole":[140],"blocked":[142],"Amphetamine":[148],"had":[149],"no":[150],"effect":[151],"behavior.":[154],"induced":[156],"hyperactivity":[157],"at":[161],"doses":[163],"tested,":[164],"while":[165],"did":[169],"not":[170,189],"significantly":[171],"affect":[172],"locomotor":[173,179],"activity.":[174],"Although":[175],"can":[177,237],"increase":[178],"activity,":[180],"control":[181],"experiments":[182],"reported":[183],"herein":[184],"indicate":[185],"hyperlocomotion":[187],"is":[188],"sufficient":[190],"produce":[192],"response":[195],"Together":[201],"with":[202],"results":[204],"paradigm,":[209],"this":[210],"suggests":[211],"reducing":[218],"anxiety":[219],"are":[220],"independent":[221],"its":[223],"locomotion.":[226],"Collectively":[227],"these":[228],"data":[229],"show":[230],"regulate":[238],"(agonist)":[244],"(antagonist)":[247],"manner.":[248]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2016589872","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":14},{"year":2013,"cited_by_count":11},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
